Phoenix Molecular Designs has been granted the Canadian patent titled "Methods of Inhibiting RSK for Treatment of Breast Cancer."

Written by Guest User

Aug. 15
2019

August 15, 2019 - The Canadian Intellectual Property Office has granted us our Method of Use Patent for inhibiting RSK for the treatment of breast cancer.

Link to the patent here

Guest User
Previous

Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibitor, Targeting Advanced Breast Cancer

Next

Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC